Ac Immune SA (ACIU) SEC Filings — 2024

Filings

• AC Immune SA Announces Key Executive Promotions — 6-K · Dec 18, 2024
• Ac Immune SA SC 13G/A Filing — SC 13G/A · Dec 13, 2024
• AC Immune SA Reports Interim Data for Down Syndrome Trial — 6-K · Dec 10, 2024
• AC Immune SA Reports Positive Phase 2 Parkinson's Trial Data — 6-K · Nov 14, 2024
• Ac Immune SA SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• AC Immune SA Files Form 6-K for November 2024 — 6-K · Nov 5, 2024
• AC Immune Appoints New Chief Medical Officer — 6-K · Sep 19, 2024
• AC Immune to Receive CHF 24.6M Milestone from Janssen — 6-K · Sep 17, 2024
• AC Immune Partner LMI Gets FDA Fast Track for Tau PET Diagnostic — 6-K · Aug 28, 2024
• AC Immune SA Files 6-K Report — 6-K · Aug 6, 2024
• AC Immune SA Replaces ATM Program with Jefferies LLC — 6-K · Aug 6, 2024
• AC Immune Unveils Novel Neurodegenerative Drug Candidates — 6-K · Jul 31, 2024
• AC Immune's Alzheimer's Drug JNJ-2056 Gets FDA Fast Track — 6-K · Jul 25, 2024
• AC Immune SA Holds Annual Meeting, Updates Shareholders — 6-K · Jun 20, 2024
• AC Immune SA Files 6-K for Shareholder Meetings — 6-K · May 21, 2024
• AC Immune SA Files Form 6-K with SEC — 6-K · May 13, 2024
• AC Immune Grants Takeda Option for ACI-24.060 — 6-K · May 13, 2024
• AC Immune SA Files 6-K, Includes 2023 Annual Report — 6-K · Mar 14, 2024
• AC Immune SA Files 20-F Annual Report for Fiscal Year Ended December 31, 2023 — 20-F · Mar 14, 2024
• AFFiRiS AG in Liqu Maintains 6.58M Share Stake in AC Immune SA — SC 13G/A · Feb 9, 2024
• AC Immune Regains Full Rights to Alzheimer's Drugs Crenezumab, Semorinemab — 6-K · Jan 22, 2024
• AC Immune Updates Phase 2 Alzheimer's & Parkinson's Trials — 6-K · Jan 3, 2024